Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

被引：2
|
作者：
Levy, Moshe Yair [1 ]
McGarry, Lisa J. [2 ]
Huang, Hui [2 ]
Lustgarten, Stephanie [2 ]
Nieset, Christopher [2 ]
Haluska, Frank G. [2 ]
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
[2] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3154.3154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Jabbour, Elias
    Apperley, Jane
    Cortes, Jorge
    Rea, Delphine
    Deininger, Michael
    Abruzzese, Elisabetta
    Chuah, Charles
    Deangelo, Daniel J.
    Hochhaus, Andreas
    Lipton, Jeffrey H.
    Mauro, Michael
    Nicolini, Franck
    Pinilla-Ibarz, Javier
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Ren, Xiaowei
    Kantarjian, Hagop
    LEUKEMIA, 2024, 38 (03) : 475 - 481
  • [22] Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Mauro, Michael
    Cortes, Jorge E.
    Apperley, Jane F.
    Gutierrez, Valentin Garcia
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sarah
    Zhang, Yifan
    Hochhaus, Andreas
    BLOOD, 2022, 140 : 6757 - 6759
  • [23] Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).
    Nicolini, Franck E.
    Lipton, Jeffrey Howard
    Kantarjian, Hagop
    Wetzler, Meir
    Akard, Luke Paul
    Baccarani, Michele
    Craig, Adam
    Nanda, Nisha
    Brown, Peter D.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Dose Modification Dynamics of Ponatinib in Patients with Chronic- Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials
    J.Jabbour, Elias
    W.Deininger, Michael
    bruzzese, Elisabetta A.
    Apperley, jane F.
    E.Cortes, Jorge
    Chuah, Charles
    J.DeAngelo, Daniel
    F.DiPersio, John
    Hochhaus, Andreas
    H.Lipton, Jeffrey
    E.Nicolini, Franck
    Ibarz, Javier Pinilla
    Rea, Delphine
    Rosti, Gianantonio
    Rousselot, Philippe
    J.Mauro, Michael
    Shah, Neil P.
    Talpaz, Moshe
    Vorog, Alexander
    Lu, Vickie
    Kantarjian, Hagop
    BLOOD, 2021, 138
  • [25] Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
    Hochhaus, Andreas
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Deininger, Michael W.
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil P.
    Kantarjian, Hagop M.
    Guilhot, Francois
    BLOOD, 2013, 122 (21)
  • [26] OUTCOMES OF THIRD-LINE BCR-ABL1 TYROSINE KINASE INHIBITORS IN THE TREATMENT FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE RECEIVED TWO PRIOR TKIS
    Lee, S. E.
    Choi, S. Y.
    Kim, S. H.
    Oh, Y. J.
    Chae, M. J.
    Song, H. Y.
    Yoo, H. L.
    Lee, M. Y.
    Jang, E. J.
    Jeong, K. H.
    Lee, J. S.
    Kim, D. W.
    HAEMATOLOGICA, 2014, 99 : 335 - 335
  • [27] Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US
    Mauro, Michael J.
    McGarry, Lisa J.
    Lustgarten, Stephanie
    Huang, Hui
    BLOOD, 2016, 128 (22)
  • [28] Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Sam, Princy Yohannan
    Ahaneku, Hycienth
    Nogueras-Gonzalez, Graciela M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Daver, Naval
    Kadia, Tapan
    Burger, Jan
    Pierce, Sherry
    DiNardo, Courtney D.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [29] Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
    Ibrahim, Amr R.
    Paliompeis, Christos
    Bua, Marco
    Milojkovic, Dragana
    Szydlo, Richard
    Khorashad, Jamshid S.
    Foroni, Letizia
    Reid, Alistair
    de Lavallade, Hugues
    Rezvani, Katayoun
    Dazzi, Francesco
    Apperley, Jane F.
    Goldman, John M.
    Marin, David
    BLOOD, 2010, 116 (25) : 5497 - 5500
  • [30] Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study.
    Saussele, Susanne
    Gambacorti-Passerini, Carlo
    Gutierrez, Valentin Garcia
    Abboud, Camille N.
    Purcell, Simon
    Viqueira, Andrea
    Leip, Eric
    Ernst, Thomas
    Giles, Frank
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345